[1] Chang JC, Wooten EC, Tsimelzon A, et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer[J]. Lancet, 2003, 362(9381): 362-369.   doi: 10.1016/S0140-6736(03)14023-8
[2] 林其声, 施雄文, 徐书楷, 等.  新辅助化疗对乳腺癌ki-67、cox-2、p53表达的影响及其临床意义[J]. 中国当代医药, 2009, 16(24): 13-14.
[3] McDermott GM, Welch A, Staff RT, et al.  Monitoring primary breast cancer throughout chemotherapy using FDG-PET[J]. Breast Cancer Res Treat, 2007, 102(1): 75-84.   doi: 10.1007/s10549-006-9316-7
[4] Schwarz-Dose J, Untch M, Tiling R, et al.  Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose[J]. J Clin Oncol, 2009, 27(4): 535-541.   doi: 10.1200/JCO.2008.17.2650
[5] 温广华, 冯彦林, 黄克敏, 等.  乳腺癌18F-FDG PET/CT标准化摄取值与Ki-67表达关系的初步研究[J]. 中国临床医学影像杂志, 2010, 21(7): 509-511.   doi: 10.3969/j.issn.1008-1062.2010.07.019
[6] 何仲琴, 李恩孝.  环氧化酶-2表达与肿瘤关系的研究进展[J]. 现代肿瘤医学, 2005, 13(4): 573-575.   doi: 10.3969/j.issn.1672-4992.2005.04.077
[7] Ruibal A, Abdulkader I, Gude F, et al.  The immunohistochemical expression of cyclooxygenase 2 is inversely associated with 18FFDG-PET SUV values in non-small-cell lung cancers[J]. Initial results. RevEspMedNucl, 2009, 28(1): 11-14.
[8] Surowiak P, Materna V, Matkowski R, et al.  Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance[J]. Breast Cancer Res, 2005, 7(5): R862-R870.   doi: 10.1186/bcr1313
[9] Denkert C, Winzer KJ, Hauptmann S.  Prognostic impact of cyclooxygenase-2 in breast cancer[J]. Clin Breast Cancer, 2004, 4(6): 428-433.   doi: 10.3816/CBC.2004.n.006
[10] Zhao X, Goswami M, Pokhriyal N, et al.  Cyclooxygenase-2 expression during immortalization and breast cancer progression[J]. Cancer Res, 2008, 68(2): 467-475.   doi: 10.1158/0008-5472.CAN-07-0782